Adds details on deal
June 17 (Reuters) - Medical equipment maker Danaher Corp DHR.N said on Thursday it would buy privately held biotech company Aldevron in an all-cash deal for about $9.6 billion.
Danaher said it expects to finance the deal using cash on hand and/or proceeds from the issuance of commercial paper.
Aldevron produces plasmid DNA, mRNA and proteins to help biotechnology and pharmaceutical customers across research, clinical and commercial fields. The company also has a deal with COVID-19 vaccine maker Moderna Inc MRNA.O to supply plasmid DNA, which is required in vaccine making.
Aldevron will operate as a standalone company and brand within Danaher's Life Sciences segment, Danaher said.
(Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj Kalluvila and Amy Caren Daniel)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Latest Technology Videos
- China quietly sets new 'buy Chinese' targets for state companies - U.S. sources
- Ottobock hires Deutsche Bank, Goldman for 2022 listing -source
- COVID SCIENCE-People with allergic reaction to mRNA vaccines can get 2nd dose; Delta variant may be 1,000 times more infectious
- U.S. approves potential sale of $3.4 bln helicopters to Israel